Table 3 Observed mortality rate according to risk class CURB65-A (based on ProADM and CURB65)
All LRTI patients (1359) | CAP patients (n = 925) | |||||
|---|---|---|---|---|---|---|
n | Adverse events (95%CI) | Mortality (95%CI) | n | Adverse events (95%CI) | Mortality (95%CI) | |
CURB65 risk classes | ||||||
CURB65 0-1 | 659 | 6.83 (4.9-8.76) | 0.76 (0.09-1.42) | 427 | 8.67 (5.99-11.34) | 0.94 (0.02-1.85) |
CURB65 2 | 434 | 14.75 (11.4-18.1) | 8.06 (5.49-10.64) | 296 | 15.54 (11.39-19.69) | 8.45 (5.26-11.63) |
CURB65 3-5 | 266 | 22.93 (17.85-28.02) | 10.15 (6.5-13.8) | 202 | 25.25 (19.21-31.29) | 10.4 (6.15-14.64) |
ProADM categories | ||||||
ProADM <0.75 nmol/l | 353 | 4.25 (2.13-6.36) | 0.85 (-0.11-1.81) | 194 | 5.67 (2.39-8.95) | 1.55 (-0.21-3.3) |
ProADM 0.75 - 1.5 nmol/l | 588 | 9.01 (6.69-11.34) | 2.72 (1.4-4.04) | 400 | 10 (7.05-12.95) | 2.75 (1.14-4.36) |
ProADM >1.5 nmol/l | 418 | 24.4 (20.27-28.54) | 11.48 (8.41-14.55) | 331 | 25.08 (20.38-29.77) | 10.88 (7.5-14.25) |
CURB65-A | ||||||
Risk class 1 | 306 | 3.92 (1.73-6.11) | 0.65 (0.25-1.56) | 167 | 5.39 (1.93-8.85) | 1.2 (0.47-2.86) |
Risk class 2 | 534 | 8.61 (6.23-11) | 2.62 (1.26-3.98) | 360 | 9.72 (6.65-12.8) | 2.78 (1.07-4.48) |
Risk class 3 | 519 | 21.58 (18.03-25.13) | 9.83 (7.26-12.4) | 398 | 22.61 (18.49-26.74) | 9.55 (6.65-12.45) |
Total | 1359 | 12.51 (10.75-14.27) | 4.93 (3.78-6.08) | 925 | 14.49 (12.21-16.76) | 5.41 (3.95-6.87) |